Leaving the study early · Adolescents with psychosis
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in leaving the study early: For any reason compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
1 finding from 1 review
Hospital admissions · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · Adolescents with psychosis
It is very uncertain whether COGNITIVE REMEDIATION THERAPY (CRG) + TREATMENT‐AS‐USUAL (TAU) changes leaving the study early: For any reason compared with TAU (all short‐term) (very low certainty).
1 finding from 1 review
Recidivism: any sexual or nonsexual offence (no study reported data on this outcome) · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects (any reported throughout the intervention period) (ALL) · treating leg cramps in pregnancy
Oral magnesium showed no clear difference in side effects ‐ any compared with placebo/no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Transepidermal water loss (TEWL) Measured using temperature‐adjusted g/m²/h with the Tewameter TM 300 (Courage + Khazaka, Cologne, Germany) Hahnel 2017: measured at 56 ± 4 days Shishido 2017: measured 15 minutes after wiping the skin with a dry to... · people 60 years of age and older
1 finding from 1 review
Development of any new foot ulcers · people with diabetes and foot ulcers
It is very uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement changes development of any new foot ulcers compared with placebo (very low certainty).
1 finding from 1 review
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · heart failure with chronic kidney disease
ACUTE: Serelaxin showed no clear difference in death (any cause) compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: ACEi or ARB showed no clear difference in death (any cause) ( compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: Beta‐blockers probably leads to lower death (any cause) ( compared with placebo (moderate certainty).
1 finding from 1 review
Hospitalisation (any cause) · heart failure with chronic kidney disease
CHRONIC: Beta‐blockers showed no clear difference in hospitalisation (any cause) compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
1 finding from 1 review